Exondys 51 Approval History
- FDA approved: Yes (First approved September 19th, 2016)
- Brand name: Exondys 51
- Generic name: eteplirsen
- Dosage form: Injection
- Company: Sarepta Therapeutics
- Treatment for: Duchenne Muscular Dystrophy
Exondys 51 (eteplirsen) is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.
The accelerated approval of Exondys 51 was based on the surrogate endpoint of increase in dystrophin in skeletal muscle observed in some patients, which the FDA concluded was reasonably likely to predict a clinical benefit, but is requiring further studies to confirm.
Exondys 51 is an intravenous infusion administered over 35 to 60 minutes once weekly. The most common side effects include balance disorder and vomiting.
Development History and FDA Approval Process for Exondys 51
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.